TG Therapeutics Inc (TGTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
TG Therapeutics Inc stock (TGTX) is currently trading at $31.82. TG Therapeutics Inc PE ratio is 10.91. TG Therapeutics Inc PS ratio (Price-to-Sales) is 7.83. Analyst consensus price target for TGTX is $44.43. WallStSmart rates TGTX as Hold.
- TGTX PE ratio analysis and historical PE chart
- TGTX PS ratio (Price-to-Sales) history and trend
- TGTX intrinsic value — DCF, Graham Number, EPV models
- TGTX stock price prediction 2025 2026 2027 2028 2029 2030
- TGTX fair value vs current price
- TGTX insider transactions and insider buying
- Is TGTX undervalued or overvalued?
- TG Therapeutics Inc financial analysis — revenue, earnings, cash flow
- TGTX Piotroski F-Score and Altman Z-Score
- TGTX analyst price target and Smart Rating
TG Therapeutics Inc
📊 No data available
Try selecting a different time range
TGTX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · TG Therapeutics Inc (TGTX)
TGTX trades 53% above its Graham fair value of $18.84, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
TG Therapeutics Inc (TGTX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, revenue growth. Concerns around price/book and eps growth. Fundamentals are solid but monitor weak areas for improvement.
TG Therapeutics Inc (TGTX) Key Strengths (6)
Every $100 of shareholder equity generates $103 in profit
Revenue surging 78.00% year-over-year
Keeps $73 of every $100 in revenue as net profit
Strong operational efficiency: $26 kept per $100 revenue
65.94% held by institutions, strong professional interest
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
TG Therapeutics Inc (TGTX) Areas to Watch (4)
Earnings declining -6.10%, profits shrinking
Very expensive at 7.5x book value
Premium valuation at 7.8x annual revenue
Growth is fairly priced, not cheap, not expensive
Supporting Valuation Data
TG Therapeutics Inc (TGTX) Detailed Analysis Report
Overall Assessment
This company scores 63/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 6 register as strengths (avg 8.8/10) while 4 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Revenue Growth, Profit Margin. Profitability is solid with Return on Equity at 102.80%, Operating Margin at 26.20%, Profit Margin at 72.60%. Growth metrics are encouraging with Revenue Growth at 78.00%.
The Bear Case
The primary concerns are EPS Growth, Price/Book, Price/Sales. Some valuation metrics including PEG Ratio (1.61), Price/Sales (7.83), Price/Book (7.45) suggest expensive pricing. Growth concerns include EPS Growth at -6.10%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 102.80% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 78.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Revenue Growth) and negatives (EPS Growth, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TGTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TGTX's Price-to-Sales ratio of 7.83x sits near its historical average of 7.69x (71th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 4% below its historical high of 8.16x set in Mar 2026, and 8% above its historical low of 7.24x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for TG Therapeutics Inc (TGTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
TG Therapeutics Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 616M with 78% growth year-over-year. Profit margins are strong at 72.6%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 78% YoY, reaching 616M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 102.8% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can TG Therapeutics Inc maintain 78%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.86, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact TG Therapeutics Inc.
Bottom Line
TG Therapeutics Inc offers an attractive blend of growth (78% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(4 last 3 months)
| Insider | Type | Shares |
|---|---|---|
CHARNEY, LAURENCE N Director | Sell | -13,197 |
| Insider | Type | Shares |
|---|---|---|
CHARNEY, LAURENCE N Director | Sell | -30,000 |
Data sourced from SEC Form 4 filings
Last updated: 4:27:19 PM
About TG Therapeutics Inc(TGTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.